These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The acyclovir legacy: its contribution to antiviral drug discovery. Darby G J Med Virol; 1993; Suppl 1():134-8. PubMed ID: 8245880 [TBL] [Abstract][Full Text] [Related]
43. Susceptibilities of phosphonoacetic acid and acyclovir resistant varicella-zoster virus mutants to 9-beta-arabinofuranosyladenine and 1-beta-arabinofuranosylcytosine. Shiraki K; Ogino T; Yamamoto T; Yamanishi K; Takahashi M Biken J; 1986 Mar; 29(1):11-7. PubMed ID: 3022709 [TBL] [Abstract][Full Text] [Related]
44. Treatment of herpesvirus infections in HIV-infected individuals. Fletcher CV Ann Pharmacother; 1992; 26(7-8):955-62. PubMed ID: 1324033 [TBL] [Abstract][Full Text] [Related]
45. Chronic varicella-zoster virus myelitis without cutaneous eruption in a patient with AIDS: report of a fatal case. Manian FA; Kindred M; Fulling KH Clin Infect Dis; 1995 Oct; 21(4):986-8. PubMed ID: 8645852 [TBL] [Abstract][Full Text] [Related]
47. Antiviral drugs for varicella-zoster virus and herpes simplex virus infections. Med Lett Drugs Ther; 2018 Sep; 60(1556):153-157. PubMed ID: 30383727 [No Abstract] [Full Text] [Related]
48. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. Boivin G; Edelman CK; Pedneault L; Talarico CL; Biron KK; Balfour HH J Infect Dis; 1994 Jul; 170(1):68-75. PubMed ID: 8014522 [TBL] [Abstract][Full Text] [Related]
49. The present and future for acyclovir. Brigden D; Keeney RE; King DH J Antimicrob Chemother; 1983 Sep; 12 Suppl B():195-9. PubMed ID: 6313599 [No Abstract] [Full Text] [Related]
50. Intravenous acyclovir for herpesvirus in immunocompromised patients. Dan M; Michaeli D; Siegman-Igra Y Isr J Med Sci; 1985 Jan; 21(1):27-31. PubMed ID: 2982763 [TBL] [Abstract][Full Text] [Related]
51. Acyclovir for intravenous use. Committee on Infectious Diseases and Immunization, Canadian Paediatric Society. Can Med Assoc J; 1984 Nov; 131(9):1045-6. PubMed ID: 6093977 [No Abstract] [Full Text] [Related]
53. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations. Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163 [TBL] [Abstract][Full Text] [Related]
54. Acyclovir resistant genital herpes virus infection in a patient with AIDS. Marrero M; Alvarez M; Millan JC; Mas Lago P; Soler M; Diaz M Acta Virol; 1991 Jan; 35(1):86-9. PubMed ID: 1683121 [TBL] [Abstract][Full Text] [Related]
55. Foscarnet therapy for AIDS-related opportunistic herpesvirus infections. Jacobson MA AIDS Clin Rev; 1992; ():173-89. PubMed ID: 1318736 [No Abstract] [Full Text] [Related]
56. [Mechanisms of antiherpes drugs and drug resistant virus--effect of BVDU on varicella zoster virus replication]. Shigeta S; Yokota T Rinsho Byori; 1985 Feb; 33(2):148-57. PubMed ID: 2987573 [No Abstract] [Full Text] [Related]
57. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus]. Morfin F; Frobert E; Thouvenot D Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384 [TBL] [Abstract][Full Text] [Related]
58. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine. Shiraki K; Ogino T; Yamanishi K; Takahashi M Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958 [TBL] [Abstract][Full Text] [Related]
59. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Perry CM; Faulds D Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821 [TBL] [Abstract][Full Text] [Related]
60. [Treatment of herpes infections with acyclovir]. Rello J Med Clin (Barc); 1987 Feb; 88(6):249-51. PubMed ID: 3031392 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]